BGBC016 STK11 NSCLC (Non-Small Cell Lung Cancer)

What is the Purpose of this Study?

We are doing this study to find out if an investigational drug called bemcentinib (the study drug) is a safe and effective option when it is combined with the standard therapy for non-small cell lung cancer (1 immunotherapy drug and 2 chemotherapy drugs).

What is the Condition Being Studied?

Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Who Can Participate in the Study?

Adults ages 18+ who are diagnosed with advanced non-squamous non-small cell lung cancer.

For more information about who can be in this study, please contact the study team at

Age Group

What is Involved?

If you join this study, you will go through a screening period to make sure you are eligible. During the screening period you will:

  • Have blood draws
  • Have imaging scans (CT and MRI)
  • Have 2 procedures to check your heart function, an electrocardiogram (ECG) and either an echocardiogram (ECHO) or a multigated acquisition scan (MUGA)

If you are eligible to get the study drug, you will:

  • Take the study drug by month once per day
  • Received the standard therapy (1 immunotherapy drug and 2 chemotherapy drugs) every 21 days by injection into a vein (IV)
  • Study Details

    Full Title
    Phase 1b/2a safety and tolerability study of bemcentinib with pembrolizumab/carboplatin/pemetrexed in subjects with untreated advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without/with a STK11 mutation.
    Principal Investigator
    Assistant Professor of Medicine
    Protocol Number
    IRB: PRO00112972
    NCT: NCT05469178
    Phase I/II
    Enrollment Status